Merrimack Pharmaceuticals Inc (MACK)
3.22
+0.05 +1.58%
NASDAQ
Feb 21, 20:00
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | -- |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.20 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -29.54M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -- |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 43.03M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 42977.34 |
| PE Ratio | -- |
| Price to Book Value | 2.140 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | -- |
| Free Cash Flow (Quarterly) | -3.203M |
| Return on Equity | Upgrade |
View All MACK News
News
-
WireHeadlineTime (ET)
-
Yahoo02/07 11:14
-
Yahoo12/22 19:44
-
MT Newswires12/03 15:52
-
MT Newswires12/03 13:53
-
SA Breaking News12/03 12:24
-
Business Wire12/03 09:15
-
SA Breaking News12/03 08:49
-
Business Wire12/03 08:45
-
MT Newswires09/24 17:02
-
PR Newswire09/24 16:45
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 03/06/2020 | Earnings | Merrimack Pharmaceuticals Inc Fourth Quarter Earnings Results in 2019 |
| 12/13/2019 | Dividends | Amount: 0.50, Declared Date: Dec 03 2019, Pay Date: Dec 23 2019 |
| 11/12/2019 | Earnings | Merrimack Pharmaceuticals Inc Third Quarter Earnings Results for 2019 |
| 09/16/2019 | Misc | Merrimack Pharmaceuticals Inc Annual General Meeting in 2018 |
| 09/06/2019 | Dividends | Amount: 1.497, Declared Date: Jul 25 2019, Pay Date: Sep 05 2019 |
| 07/17/2019 | Earnings | Merrimack Pharmaceuticals Inc Second Quarter Earnings Results in 2019 |
| 05/10/2019 | Earnings | Merrimack Pharmaceuticals Inc First Quarter Earnings Results in 2019 |
| 03/06/2019 | Earnings | Merrimack Pharmaceuticals Inc Fourth Quarter Earnings in 2018 Release |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.merrimack.com
- Investor Relations URL: http://investors.merrimackpharma.com/
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: Mar. 06, 2020
- Last Earnings Release: Nov. 12, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Dec. 13, 2019
- Description: Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 3.22 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| KRXCX | Kinetics Medical Adv C | 0.22% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- MACK Tweets Stocktwits
Advertisement
